Immunic (IMUX) Projected to Post Earnings on Wednesday

Immunic (NASDAQ:IMUX) is expected to announce its Q1 2025 earnings results before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.26) per share for the quarter.

Immunic Stock Performance

Shares of NASDAQ:IMUX opened at $0.99 on Tuesday. Immunic has a 52-week low of $0.83 and a 52-week high of $2.11. The company has a fifty day moving average of $1.07 and a 200-day moving average of $1.09. The company has a market capitalization of $94.54 million, a PE ratio of -0.80 and a beta of 1.73.

Analysts Set New Price Targets

IMUX has been the topic of a number of research reports. D. Boral Capital reissued a “buy” rating and set a $17.00 target price on shares of Immunic in a report on Wednesday, April 30th. StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a research report on Thursday, March 20th. William Blair began coverage on Immunic in a research note on Tuesday, March 25th. They issued an “outperform” rating for the company. B. Riley reissued a “buy” rating and set a $6.00 target price on shares of Immunic in a research report on Wednesday, April 16th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Immunic in a research report on Thursday, May 1st. One analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $13.20.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.